Lipase Elevation in Patients With COVID-19
- PMID: 32496339
- PMCID: PMC7288768
- DOI: 10.14309/ajg.0000000000000732
Lipase Elevation in Patients With COVID-19
Abstract
Introduction: Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19.
Methods: A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19.
Results: Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms.
Discussion: Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.
Conflict of interest statement
References
-
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: Revision of the atlanta classification and definitions by international consensus. Gut 2013;62(1):102–11. - PubMed
-
- Jin DX, Yang AL, Suleiman SL, et al. Marked serum lipase elevations are associated with longer hospitalizations in patients with non-pancreatic hyperlipasemia. Gastroenterology. 2019;156(6):S-1033–S-1034.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
